Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Restless Legs Syndrome

In brief

The objective of the study was to generate the data necessary to determine the gabapentin exposure produced by 4 dose levels of GEn (600 mg, 1200 mg, 1800 mg, and 2400 mg) or placebo, and the corresponding relief of symptoms in subjects with Restless Legs Syndrome (RLS).

Key facts

Study ID

NCT01332305

Run by

XenoPort, Inc.

People needed

217

Starts

2007-01-01

Expected to finish

2008-01-01

Last updated by the study team

2013-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women at least 18 years of age
• RLS, based on the IRLSSG Diagnostic Criteria
• History of RLS symptoms occurring at least 15 nights in the month prior to Screening or, if on RLS treatment, this frequency of symptoms must have been applicable prior to start of treatment
• Documented RLS symptoms for at least 4 of the 7 consecutive evenings/nights
• Total RLS severity score of 15 or greater on the IRLS Rating Scale
• If taking dopamine agonists, gabapentin, or other treatments for RLS (e.g., opioids, benzodiazepines) medications must have been discontinued at least 2 weeks prior to Screening;
• If taking any prescription medication, therapy must have been stabilized for at least 3 months prior to Screening with no anticipated changes for the duration of the study;
• Body Mass Index (BMI) of 34 or below
• estimated creatinine clearance of at least 60 mL/min

You may not qualify if…

• a sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of RLS
• history of RLS symptom augmentation or end of dose rebound with previous dopamine agonist treatment
• neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's disease, multiple sclerosis, dyskinesias, and dystonias);
• other clinically significant or unstable medical condition or conditions which could affect RLS treatment efficacy assessments
• serum ferritin level below 20 ng/mL
• currently suffering from moderate or severe depression using the Diagnostic and Statistical Manual of Mental Disorders and Treatment IV (DSM IV TR)

Where it is running

• GSK Investigational Site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.